Contribution: Industrial Research Assistance Program – Contributions to Firms
Waverley Pharma Inc
$180,000.00
Development of Technical Capabilities for Product Development
FY 2018-19 · 2018-04-02
Summary
The aim of the project is to develop and commercialize pharmaceutical drugs for the treatment of cancer. The Company's current focus is on the generic oncology generic injectible market in the European Union and North America. Currently, Waverley Pharma Inc. has two products WAV-101 and WAV-102 for the treatment of cancer.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Winnipeg|Winnipeg, Manitoba, Canada
Recipient Type
For-profit organization
Business Number
737463927
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2018-04-02 | 2018-19 | $91,400.00 |
| 1 | 2018-04-02 | 2018-19 | $180,000.00 |
| 3 | 2018-04-02 | 2018-19 | $180,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 30 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 30 jours.
Agreement End Date
2021-02-28
Agreement Number
901202
Agreement Start Date
2018-04-02
Agreement Title
Development of Technical Capabilities for Product Development
Agreement Title (French)
Développement des capacités techniques pour le développement de produits
Agreement Type
Contribution
Agreement Value
$180,000.00
Amendment Date
2020-12-16
Amendment Number
3
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The aim of the project is to develop and commercialize pharmaceutical drugs for the treatment of cancer. The Company's current focus is on the generic oncology generic injectible market in the European Union and North America. Currently, Waverley Pharma Inc. has two products WAV-101 and WAV-102 for the treatment of cancer.
Description (French)
Le but du projet est de développer et de commercialiser des médicaments pharmaceutiques pour le traitement du cancer. L'accent actuel de l'entreprise est mis sur le marché d’oncologie générique injectable dans l’Union européenne et l’Amérique du Nord. À l’heure actuelle, Waverley Pharma Inc. a deux produits, WAV-101 et WAV-102, pour le traitement du cancer.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Winnipeg South Centre
Federal Riding (French)
Winnipeg-Centre-Sud
Federal Riding Number
46014
NAICS Code
3254
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
737463927
Recipient City
Winnipeg|Winnipeg
Recipient Country
CA
Recipient Legal Name
Waverley Pharma Inc
Recipient Postal Code
R3T 6C6
Recipient Province or Territory
MB
Recipient Type
F
Reference Number
172-2018-2019-Q1-901202
